Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
株式のランク #12088
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
株価
$2.34
最終同期: 2026-08-28
時価総額
$621.44M
変化(1日)
-1.06%
変化(1年)
55.67%
GB
取引 Autolus Therapeutics plc (AUTL)

カテゴリー

Autolus Therapeutics plc(AUTL)の株価履歴
終値の最高値: $2.28 (2026-08-01)

終値の最安値: $26.43 (2018-06-01)
Autolus Therapeutics plc の株価履歴(2018 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.20 -12.94%
AU
$138.18 473.58%
US
$759.27 7.20%
CH